Clonal cytotoxic T cells are expanded in myeloma and reside in the CD8+CD57+CD28- compartment

被引:114
作者
Sze, DMY [1 ]
Giesajtis, G
Brown, RD
Raitakari, M
Gibson, J
Ho, J
Baxter, AG
Fazekas de St Groth, B
Basten, A
Joshua, DE
机构
[1] Royal Prince Alfred Hosp, Inst Haematol, Camperdown, NSW 2050, Australia
[2] Centenary Inst Canc Med & Cell Biol, Newtown, NSW, Australia
[3] Turku Univ, Cent Hosp, Dept Clin Chem, Turku, Finland
关键词
D O I
10.1182/blood.V98.9.2817
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The occurrence of clonal T cells in multiple myeloma (MM), as defined by the presence of rearrangements in the T-cell receptor (TCR)-beta chains detected on Southern blotting, is associated with an improved prognosis. Recently, with the use of specific anti-TCR-variable-beta (anti-TCRVbeta) antibodies, the presence in MM patients of expanded populations of T cells expressing particular V-beta regions was reported. The majority of these T-cell expansions have the phenotype of cytotoxic T cells (CD8(+)CD57(+) and perforin positive). Since V-beta expansions can result from either a true clonal population or a polyclonal response, the clonality of CD8(+)TCRV(beta)(+) T cells was tested by TCRVbeta complementarity-determining region 3 length analysis and DNA sequencing of the variable region of the TCR. In this report, the CD57(+) and CD57(-) subpopulations within expanded TCRV(beta)(+)CD8(+) cell populations are compared, and it is demonstrated that the CD57(+) subpopulations are generally monoclonal or biclonal, whereas the corresponding CD57(-) cells are frequently polyclonal. The oligoclonality of CD57(+) expanded CD8(+) T cells but not their CD57(-) counterparts was also observed in age-matched controls, in which the T-cell expansions were mainly CD8(-). The CD8(+)CD57(+) clonal T cells had a low rate of turnover and expressed relatively lower levels of the apoptotic marker CD95 than their CD57(-) counterparts. Taken together, these findings demonstrate that MM is associated with CD57(+)CD8(+) T-cell clones, raising the possibility that the expansion and accumulation of activated clonal CD8(+) T cells in MM may be the result of persistent stimulation by tumor-associated antigens, combined with a reduced cellular death rate secondary to reduced expression of the apoptosis-related molecule CD95. (C) 2001 by The American Society of Hematology.
引用
收藏
页码:2817 / 2827
页数:11
相关论文
共 52 条
[1]  
AUTRAN B, 1991, BLOOD, V77, P2237
[2]   Bone marrow derived dendritic cells from patients with multiple myeloma cultured with three distinct protocols do not bear Kaposi's sarcoma associated herpesvirus DNA [J].
Bellos, F ;
Goldschmidt, H ;
Dörner, M ;
Ho, AD ;
Moos, M .
ANNALS OF ONCOLOGY, 1999, 10 (03) :323-327
[3]   NAIVE CD4(+) T-CELLS CONFER IDIOTYPE-SPECIFIC TUMOR RESISTANCE IN THE ABSENCE OF ANTIBODIES [J].
BOGEN, B ;
MUNTHE, L ;
SOLLIEN, A ;
HOFGAARD, P ;
OMHOLT, H ;
DAGNAES, F ;
DEMBIC, Z ;
LAURITZSEN, GF .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (11) :3079-3086
[5]   IDIOTOPE-SPECIFIC T-CELL CLONES THAT RECOGNIZE SYNGENEIC IMMUNOGLOBULIN FRAGMENTS IN THE CONTEXT OF CLASS-II MOLECULES [J].
BOGEN, B ;
MALISSEN, B ;
HAAS, W .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1986, 16 (11) :1373-1378
[6]   The prognostic significance of T cell receptor beta gene rearrangements and idiotype-reactive T cells in multiple myeloma [J].
Brown, RD ;
Yuen, E ;
Nelson, M ;
Gibson, J ;
Joshua, D .
LEUKEMIA, 1997, 11 (08) :1312-1317
[7]   Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells [J].
Chauhan, D ;
Bharti, A ;
Raje, N ;
Gustafson, E ;
Pinkus, GS ;
Pinkus, JL ;
Teoh, G ;
Hideshima, T ;
Treon, SP ;
Fingeroth, JD ;
Anderson, KC .
BLOOD, 1999, 93 (05) :1482-1486
[8]   Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells [J].
Dabadghao, S ;
Bergenbrant, S ;
Anton, D ;
He, W ;
Holm, G ;
Yi, Q .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 100 (04) :647-654
[9]   Syndecan-1 is a multifunctional regulator of myeloma pathobiology: Control of tumor cell survival, growth, and bone cell differentiation [J].
Dhodapkar, MV ;
Abe, E ;
Theus, A ;
Lacy, M ;
Langford, JK ;
Barlogie, B ;
Sanderson, RD .
BLOOD, 1998, 91 (08) :2679-2688
[10]  
Fagerberg J, 1999, INT J CANCER, V80, P671, DOI 10.1002/(SICI)1097-0215(19990301)80:5<671::AID-IJC7>3.0.CO